Sandoz granted novel biosimilars approval
The approval authorises the interchangeability of denosumab biosimilars in the US to treat primary and secondary bone loss.
List view / Grid view
The approval authorises the interchangeability of denosumab biosimilars in the US to treat primary and secondary bone loss.
An integrated Phase I/III trial has enrolled its first patient to test a biosimilar for denosumab to treat postmenopausal osteoporosis.